The clinical significance of antimicrobial serologic responses within an Irish Crohn's disease population

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 12, 2013, Pages 1464-1469

  O'Donnell, Sarah ^a   O'Sullivan, Maria ^a   O'Morain, Colm A ^a   Ryan, Barbara M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

ANCA; anti CBir; anti ompC; ASCA; Crohn's disease; Irish; microbial antigen

Indexed keywords

ADALIMUMAB; ANTIBODY; ANTIINFECTIVE AGENT; CBIR ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; SACCHAROMYCES CEREVISIAE PROTEIN; SACCHAROMYCES CERVISIAE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POPULATION; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGE FACTORS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, BACTERIAL; ANTIGENS, FUNGAL; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PORINS; SACCHAROMYCES CEREVISIAE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84887049842     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328365a364     Document Type: Article

References (32)

1. Cobrin GM, Abreu MT. Defects in mucosal immunity leading in Crohn's disease. Immunol Rev 2005; 206:277-295.
2. Devlin SM,Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007; 132:576-586.
3. Landers CJ, Cohavy O, Misra R, Yang H, Lin YC, Braun J, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto-and microbial antigens. Gastroenterology 2002; 123:689-699.
4. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235-2241.
5. Brandwein SL, McCabe RP, Cong Y,Waites KB, Ridwan BU, Dean PA, et al. Spontaneously colitic C3h/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric flora. J Immunol 1997; 159:44-52.
6. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (baker's yeast) in Crohn's disease. BMJ 1988; 297:1105-1106.
7. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 2005; 128:2020-2026.
8. Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, et al. Antibodies against laminaribioside and chitobioside are novel serological markers in Crohn's disease. Gastroenterolgy 2006; 131:366-378.
9. Bairead E, Harmon DL, Curtis AM, Kelly Y, O'Leary C, Gardner M, et al. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet 2003; 11:237-244.
10. Arnott IDR, Nimmo ER, Drummond HE, Fennell BRK, MacKinlay E, Morecroft J, et al. NOD2/CARD15, TLR4 and CD4 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun 2004; 5:417-425.
11. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA assays in inflammatory bowel disease. Gastroenterology 2001; 120:827-833.
12. Kim BC, Park S, Han J, Kim JH, Kim WH. Clinical Significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis 2007; 39:610-616.
13. Hadrich I, Vandewalle P, Heikrouhou F, Makni F, Krichen MS, Sendid B, et al. Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors. Scand J Gastroenterol 2007; 42:717-725.
14. Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behaviour and NOD2/ CARD 15 genotype, but not with risk for surgery in a Hungarian cohort of IBD. Inflamm Bowel Dis 2007; 13:984-992.
15. Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, et al. Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis 2007; 13:143-151.
16. Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, et al. CARD 15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin Exp Immunol 2005; 140:354-359.
17. Arnott IDR, Landers CJ, Nimmo EJ, Drummond HE, Smith BKR, Targan SR, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99:2376-2384.
18. Lawrence IC, Murray K, Hall A, Sung JJ, Leong R. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients. Am J Gastroenterol 2004; 99:2186-2194.
19. Teml A, Kratzer V, Schneider B, Lochs H, Norman GL, Gangl A, et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003; 98:2226-2231.
20. Hisabe T, Matsui T, Sakurai T, Murakami Y, Tanabe H, Matake H, et al. Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value. J Gastroenterol 2003; 38:121-126.
21. Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, et al. Familial expression of anti-Saccharomyces cerevisiae Mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001; 96:2407-2412.
22. Peeters M, Joossens S, Vermiere S, Vlietinck R, Bossuyt X, Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730-734.
23. Koutroubakis IE, Petinali E, Mouzas IA, Vlachonikolis IG, Anagnostopoulou E, Castanas E, et al. Anti-Saccharomyces cerevisiae Mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96:449-454.
24. Linskens RK, Maleant-Hent RC, Murillo LS, von Blomberg BM, Alizadeh BZ, Pena AS. Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn's disease population. Dig Liver Dis 2004; 36:29-34.
25. Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease. Inflamm Bowel Dis 2004; 10:521-528.
26. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414-424.
27. Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, et al. Bacterial flagellin is a dominant antigen in Crohn's disease. J Clin Invest 2004; 113:1296-1306.
28. Papadakis KA, Yang H, Ippoliti A, Elson CO, Hershberg RM, Vasiauskas EA, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007; 13:524-530.
29. Vasaliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogenous subgroups with distinct clinical characteristics. Gut 2000; 47:487-496.
30. Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, et al. New serologic markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007; 56:1394-1403.
31. Israeli E, Grotto I, Gilburd B, Balicer RD, Goldin E, Wiik A, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005; 54: 1232-1236.
32. Eser A, Papay P, Primas C, Pernicka E, Harrer M, Dejaco C, et al. The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease. Aliment Pharmacol Ther 2012; 35:292-299.